Pacer Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-461
| Closed | -$112K | – | 2536 |
|
|
2024
Q2 | $112K | Buy |
461
+176
| +62% | +$42.8K | ﹤0.01% | 2215 |
|
|
2024
Q1 | $42.6K | Buy |
+285
| New | +$42.6K | ﹤0.01% | 3233 |
|
|
2021
Q2 | – | Sell |
-550
| Closed | -$78K | – | 1409 |
|
|
2021
Q1 | $78K | Sell |
550
-472
| -46% | -$66.9K | ﹤0.01% | 1326 |
|
|
2020
Q4 | $133K | Buy |
1,022
+184
| +22% | +$23.9K | ﹤0.01% | 1312 |
|
|
2020
Q3 | $122K | Buy |
+838
| New | +$122K | ﹤0.01% | 1233 |
|
|
2018
Q4 | – | Sell |
-2,640
| Closed | -$231K | – | 553 |
|
|
2018
Q3 | $231K | Buy |
+2,640
| New | +$231K | 0.01% | 1001 |
|
|
2018
Q1 | – | Sell |
-1,525
| Closed | -$194K | – | 1042 |
|
|
2017
Q4 | $194K | Sell |
1,525
-10,241
| -87% | -$1.3M | 0.01% | 908 |
|
|
2017
Q3 | $1.38M | Buy |
11,766
+156
| +1% | +$18.3K | 0.12% | 158 |
|
|
2017
Q2 | $926K | Buy |
11,610
+2,093
| +22% | +$167K | 0.09% | 274 |
|
|
2017
Q1 | $488K | Buy |
9,517
+1,544
| +19% | +$79.2K | 0.06% | 494 |
|
|
2016
Q4 | $299K | Buy |
7,973
+386
| +5% | +$14.5K | 0.04% | 694 |
|
|
2016
Q3 | $514K | Buy |
7,587
+657
| +9% | +$44.5K | 0.08% | 353 |
|
|
2016
Q2 | $385K | Buy |
6,930
+5,790
| +508% | +$322K | 0.06% | 451 |
|
|
2016
Q1 | $72K | Buy |
1,140
+55
| +5% | +$3.47K | 0.02% | 712 |
|
|
2015
Q4 | $102K | Buy |
+1,085
| New | +$102K | 0.02% | 580 |
|